Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 4
1947 5
1948 3
1949 6
1950 13
1951 11
1953 2
1954 1
1955 3
1956 4
1957 3
1959 2
1960 1
1961 4
1962 1
1965 1
1966 1
1967 1
1968 3
1969 3
1970 2
1971 3
1972 8
1973 6
1974 3
1975 6
1976 10
1977 4
1978 7
1979 9
1980 16
1981 8
1982 5
1983 3
1984 14
1985 6
1986 12
1987 8
1988 6
1989 9
1990 14
1991 17
1992 14
1993 13
1994 11
1995 11
1996 8
1997 21
1998 13
1999 36
2000 26
2001 36
2002 16
2003 28
2004 28
2005 32
2006 29
2007 28
2008 23
2009 28
2010 41
2011 42
2012 55
2013 48
2014 51
2015 43
2016 61
2017 70
2018 56
2019 69
2020 80
2021 75
2022 96
2023 86
2024 42

Text availability

Article attribute

Article type

Publication date

Search Results

1,409 results

Results by year

Filters applied: . Clear all
Page 1
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Salles G, Duell J, González Barca E, Tournilhac O, Jurczak W, Liberati AM, Nagy Z, Obr A, Gaidano G, André M, Kalakonda N, Dreyling M, Weirather J, Dirnberger-Hertweck M, Ambarkhane S, Fingerle-Rowson G, Maddocks K. Salles G, et al. Among authors: andre m. Lancet Oncol. 2020 Jul;21(7):978-988. doi: 10.1016/S1470-2045(20)30225-4. Epub 2020 Jun 5. Lancet Oncol. 2020. PMID: 32511983 Clinical Trial.
Health effects and known pathology associated with the use of E-cigarettes.
Esteban-Lopez M, Perry MD, Garbinski LD, Manevski M, Andre M, Ceyhan Y, Caobi A, Paul P, Lau LS, Ramelow J, Owens F, Souchak J, Ales E, El-Hage N. Esteban-Lopez M, et al. Among authors: andre m. Toxicol Rep. 2022 Jun 16;9:1357-1368. doi: 10.1016/j.toxrep.2022.06.006. eCollection 2022. Toxicol Rep. 2022. PMID: 36561957 Free PMC article. Review.
Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Morschhauser F, et al. Among authors: andre m. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. N Engl J Med. 2018. PMID: 30184451 Free PMC article. Clinical Trial.
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G. Duell J, et al. Among authors: andre m. Haematologica. 2021 Sep 1;106(9):2417-2426. doi: 10.3324/haematol.2020.275958. Haematologica. 2021. PMID: 34196165 Free PMC article. Clinical Trial.
Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial.
Fornecker LM, Lazarovici J, Aurer I, Casasnovas RO, Gac AC, Bonnet C, Bouabdallah K, Feugier P, Specht L, Molina L, Touati M, Borel C, Stamatoullas A, Nicolas-Virelizier E, Pascal L, Lugtenburg P, Di Renzo N, Vander Borght T, Traverse-Glehen A, Dartigues P, Hutchings M, Versari A, Meignan M, Federico M, André M; LYSA-FIL-EORTC Intergroup. Fornecker LM, et al. Among authors: andre m. J Clin Oncol. 2023 Jan 10;41(2):327-335. doi: 10.1200/JCO.21.01281. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867960 Free article. Clinical Trial.
Effet d’un traitement par hydroxychloroquine prescrit comme traitement de fond de rhumatismes inflammatoires chroniques ou maladies auto-immunes systémiques sur les tests diagnostiques et l’évolution de l’infection à SARS CoV-2 : étude de 871 patients.
Trefond L, Drumez E, Andre M, Costedoat-Chalumeau N, Seror R, Devaux M, Dernis E, Dieudonne Y, El Mahou S, Lanteri A, Melki I, Queyrel V, Roumier M, Schmidt J, Barnetche T, Thomas T, Cacoub P, Belot A, Aumaitre O, Richez C, Hachulla E; FAI2R SFR SNFMI SOFREMIP CRI IMIDIATE consortium et contributeurs. Trefond L, et al. Among authors: andre m. Rev Rhum Ed Fr. 2022 Mar;89(2):192-195. doi: 10.1016/j.rhum.2021.09.004. Epub 2021 Sep 29. Rev Rhum Ed Fr. 2022. PMID: 34602813 Free PMC article. French. No abstract available.
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study.
Bettiol A, Urban ML, Bello F, Fiori D, Mattioli I, Lopalco G, Iannone F, Egan A, Dagna L, Caminati M, Negrini S, Bargagli E, Folci M, Franceschini F, Padoan R, Flossmann O, Solans R, Schroeder J, André M, Moi L, Parronchi P, Roccatello D, Sciascia S, Jayne D, Prisco D, Vaglio A, Emmi G; European EGPA Study Group. Bettiol A, et al. Among authors: andre m. Ann Rheum Dis. 2022 Dec;81(12):1769-1772. doi: 10.1136/ard-2022-222776. Epub 2022 Jul 18. Ann Rheum Dis. 2022. PMID: 35850947 No abstract available.
Reply.
de Parisot A, Jamilloux Y, Kodjikian L, Errera MH, Sedira N, Heron E, Pérard L, Cornut PL, Schneider C, Rivière S, Ollé P, Pugnet G, Cathébras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Vicente S, Bin S, Broussolle C, Decullier E, Sève P. de Parisot A, et al. Among authors: andre m. Am J Ophthalmol. 2017 Jul;179:208-209. doi: 10.1016/j.ajo.2017.04.023. Epub 2017 May 17. Am J Ophthalmol. 2017. PMID: 28528083 No abstract available.
Adipose tissue is a source of regenerative cells that augment the repair of skeletal muscle after injury.
Sastourné-Arrey Q, Mathieu M, Contreras X, Monferran S, Bourlier V, Gil-Ortega M, Murphy E, Laurens C, Varin A, Guissard C, Barreau C, André M, Juin N, Marquès M, Chaput B, Moro C, O'Gorman D, Casteilla L, Girousse A, Sengenès C. Sastourné-Arrey Q, et al. Among authors: andre m. Nat Commun. 2023 Jan 5;14(1):80. doi: 10.1038/s41467-022-35524-7. Nat Commun. 2023. PMID: 36604419 Free PMC article.
1,409 results